Bio International 2024

ReciBioPharm seizes viral and nucleic acid therapeutics opportunity and more at BIO 2024

By Isabel Cameron

- Last updated on GMT

© Getty Images
© Getty Images

Related tags CDMO Contract manufacturing Manufacturing facility Supply chain

Daniel Spurgin, director of strategic partnerships at ReciBioPharm, unveiled the company's BIO 2024 plans and how the CDMO is set to flourish as more viral and nucleic acid therapeutics move to the clinic in the next two years.

BPR: What new products or innovations is your company showcasing at BIO 24?

This year, we’re showcasing our fully integrated, digitally controlled, nested RNA manufacturing platform.

BPR: What are you hoping to achieve from the event?

We aim to share our innovations with mRNA developers and look forward to connecting with new friends and family of ReciBioPharm.

BPR: How does your company stay ahead of industry trends and developments in the pharmaceutical sector? ​ 

We listen to customers’ requirements for flexibility, transparency and end-to-end CDMO services under one roof.

BPR: What challenges are you currently facing in the pharmaceutical market, and how is your organization addressing them?​ 

There’s a limited understanding of what is happening in-process during mRNA manufacturing, with batches gated via classical quality control (QC) methods. We are developing in-line process analytics and digital twins to better anticipate and characterize bioprocesses in real time.

BPR: What strategies does your company employ to ensure the quality & safety of its pharmaceutical products?

We employ process analytics and a large panel of prequalified assays as well as drug master files (DMFs) registered with Health Canada and the U.S. Food and Drug Administration (FDA).

BPR: Can you provide insights into any regulatory changes or compliance issues that are impacting your business?

A key issue impacting mRNA therapeutics is the lack of product definition and characterization for nucleic acid therapeutics as few of these therapies are currently commercialized.

BPR: Can you discuss any plans for expansion or market growth in the pipeline? ​ 

We believe a large number of viral and nucleic acid therapeutics will be moving to the clinic in the next two years. This will create opportunities for CDMOs like ReciBioPharm to support discovery, help get therapies to and through clinical trials, and be the trusted manufacturer of lifesaving commercialized advanced therapy medicinal products (ATMPs).

BPR: What sets your company apart from competitors in the pharmaceutical industry, and what value do you offer to your customers? 

We are the industry’s leading innovators in AI-enabled continuous manufacturing of encapsulated RNA. We’re also the experts in plasmid, nucleic acid manufacturing, adeno-associated viral vector (AAV) production and microbiome development and manufacturing, providing end-to-end services under one roof.

Related news

Follow us